Distinct Healthcare Files for Hong Kong IPO to Expand Integrated Medical Services
CompanyDeals

Distinct Healthcare Files for Hong Kong IPO to Expand Integrated Medical Services

Pfizer Restructures China Operations to Boost Growth and Innovation
Company

Pfizer Restructures China Operations to Boost Growth and Innovation

CDE's 2024 Annual Drug Review Report Shows Continued Growth in Regulatory Filings
Policy / Regulatory

CDE’s 2024 Annual Drug Review Report Shows Continued Growth in Regulatory Filings

Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production
Company

Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production

GE Healthcare and NVIDIA Expand Partnership to Advance Autonomous X-ray and Ultrasound Technologies
CompanyDeals

GE Healthcare and NVIDIA Expand Partnership to Advance Autonomous X-ray and Ultrasound Technologies

Tonghua Dongbao Initiates Phase III Trial for Insulin Degludec, Liraglutide Combo in Type 2 Diabetes
CompanyDrug

Tonghua Dongbao Initiates Phase III Trial for Insulin Degludec, Liraglutide Combo in Type 2 Diabetes

Formosa Pharmaceuticals Inks Licensing Pact with Cipla for APP13007 in 11 Countries
CompanyDeals

Formosa Pharmaceuticals Inks Licensing Pact with Cipla for APP13007 in 11 Countries

AccurEdit Therapeutics Receives FDA Orphan Drug Designation for ATTR Treatment
CompanyDrug

AccurEdit Therapeutics Receives FDA Orphan Drug Designation for ATTR Treatment

Johnson & Johnson's Nipocalimab Receives FDA Fast Track Designation for Sjögren's Disease
CompanyDrug

Johnson & Johnson’s Nipocalimab Receives FDA Fast Track Designation for Sjögren’s Disease

Medbanks Reports 2024 Financial Results Amid Business Reorganization
Company

Medbanks Reports 2024 Financial Results Amid Business Reorganization

AstraZeneca's Imfinzi Approved in EU for Limited-Stage Small Cell Lung Cancer
CompanyDrug

AstraZeneca’s Imfinzi Approved in EU for Limited-Stage Small Cell Lung Cancer

HutchMed and Innovent Announce Positive Results for Fruquintinib and Sintilimab in Renal Cell Carcinoma Trial
CompanyDrug

HutchMed and Innovent Announce Positive Results for Fruquintinib and Sintilimab in Renal Cell Carcinoma Trial